Dr. Albiges on Immunotherapy in Renal Cell Carcinoma

Laurence Albiges, MD
Published Online: Monday, Oct 17, 2016



Laurence Albiges, MD, ‎medical oncologist, head, Genitourinary Oncology Unit, Gustave Roussy, discusses how immunotherapy has had an impact on the field of renal cell carcinoma (RCC).

The field has been evolving for some time, Albiges explains. However, exciting immuno-oncology results were presented at the 2015 ESMO Congress. It was here that the findings of a phase III study exploring nivolumab (Opdivo) compared with everolimus (Afinitor) showed that, in patients who failed on 1 or 2 anti-VEGF therapies, there is a role for immunotherapy.

This has made an impact on the standard of care. Next steps, she adds, will include combination studies of immunotherapy agents as an effort to elicit a greater benefit. 


Laurence Albiges, MD, ‎medical oncologist, head, Genitourinary Oncology Unit, Gustave Roussy, discusses how immunotherapy has had an impact on the field of renal cell carcinoma (RCC).

The field has been evolving for some time, Albiges explains. However, exciting immuno-oncology results were presented at the 2015 ESMO Congress. It was here that the findings of a phase III study exploring nivolumab (Opdivo) compared with everolimus (Afinitor) showed that, in patients who failed on 1 or 2 anti-VEGF therapies, there is a role for immunotherapy.

This has made an impact on the standard of care. Next steps, she adds, will include combination studies of immunotherapy agents as an effort to elicit a greater benefit. 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Consultations®: Identifying Best Practices of the Multidisciplinary Team in CINV ManagementJun 28, 20172.0
Community Practice Connections™: A Team-Based Approach to Enhanced Recovery: Controlling Postsurgical Pain in Breast Cancer PatientsJun 29, 20172.0
Publication Bottom Border
Border Publication
$emailPop$